Sign In
Buy COLL
$31.06
+0.580 (+1.90%)
At Close: Jun 03, 2026
All You Need to Know About Collegium Pharmaceutical (COLL) Rating Upgrade to Strong Buy
01:01pm, Thursday, 25'th Sep 2025
Collegium Pharmaceutical (COLL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near ter
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
10:41am, Tuesday, 23'rd Sep 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Collegium Pharmaceutical, Inc. (COLL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
05:03pm, Monday, 08'th Sep 2025
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Vikram Karnani - CEO, President, Executive VP &
Collegium to Participate in Upcoming Investor Conferences
08:00am, Thursday, 28'th Aug 2025
STOUGHTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 2025 Well
Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting
08:00am, Monday, 25'th Aug 2025
STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain p
Collegium Pharmaceutical, Inc. (COLL) Q2 2025 Earnings Call Transcript
02:00pm, Thursday, 07'th Aug 2025
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Colleen Tupper - Executive VP & CFO Ian Karp - Corporate Participant Scott
Collegium (COLL) Q2 Revenue Jumps 29%
10:51am, Thursday, 07'th Aug 2025
Collegium (COLL) Q2 Revenue Jumps 29%
Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics
10:36am, Thursday, 07'th Aug 2025
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare w
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates
09:50am, Thursday, 07'th Aug 2025
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.68 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.62 per share a year ago.
Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook
07:30am, Thursday, 07'th Aug 2025
– Generated Record Quarterly Net Revenue of $188.0 Million, Up 29% Year-over-Year – – Generated Record Quarterly Jornay PM ® Net Revenue of $32.6 Million and Grew Prescriptions by 23% Year-ove
Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High?
10:56am, Friday, 25'th Jul 2025
The consensus price target hints at a 33.9% upside potential for Collegium Pharmaceutical (COLL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
10:41am, Friday, 25'th Jul 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025
08:00am, Thursday, 24'th Jul 2025
STOUGHTON, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report second quarter 2025 financial results before the market opens on�
5 Hot Stocks With Summer Buybacks You Can Cash In On
04:09pm, Thursday, 10'th Jul 2025
Stock buybacks remain one of the most effective tools for boosting share prices, especially when backed by solid fundamentals. When a company is healthy, repurchasing shares reduces the float, enhance
Collegium Announces $150 Million Share Repurchase Program
08:00am, Monday, 07'th Jul 2025
STOUGHTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living w
